Korea:328130

Lunit Meets MDR CE Requirements for 3D Breast Tomosynthesis AI Solution

* Lunit set to launch Lunit INSIGHT DBT in the European market * Lunit seeks FDA clearance, paving the way into the US market SEOUL, South Korea, March 20, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer solutions, today announced that its AI solution...

2023-03-20 21:00 1556

Lunit to Present 5 Abstracts at the 2023 AACR Annual Meeting

* Five posters from Lunit and collaborators demonstrate important progress in the development of novel diagnostics for important cancer therapies, including immunotherapy SEOUL, South Korea, March 15, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer sol...

2023-03-15 21:14 2204

Lunit to Establish Subsidiary in Europe to Accelerate Business Expansion

* Lunit to establish new subsidiary, Lunit Europe Holdings, to expand sales network acrossEurope and strengthen global capabilities SEOUL, South Korea, Feb. 17, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of AI-powered cancer solutions, today announced its decision to establis...

2023-02-17 21:12 4040

Randomized Controlled Trial Backs Clinical Efficacy of Lunit AI for Chest X-Ray

* First-ever randomized controlled trial regarding deep learning-based AI in radiology provides strong evidence for the clinical value of AI * Large-scale study with 10,476 patients published in Radiology, the top journal in radiology SEOUL, South Korea, Feb. 13, 2023 /PRNewswire/ -- Findings ...

2023-02-13 21:00 1897

Lunit and Agfa HealthCare bring breast imaging AI solution to Dubai Academic Health Corporation (DAHC) Dubai Hospital

* Dubai Academic Health Corporation (DAHC) Dubai Hospital to modernize its Breast Cancer Diagnostic and Screening program with Agfa HealthCare's RUBEE for AI framework and Lunit INSIGHT MMG algorithm * The Breast AI Analysis Package is Lunit's first application with Agfa HealthCare since form...

2023-02-08 21:05 2228

Guardant Health to integrate Lunit's AI-based scoring algorithm for PD-L1 into its portfolio to enhance cancer biomarker detection

* Powered by Lunit SCOPE PD-L1, the Guardant360 TissueNext PD-L1 test with Guardant Galaxy™ shows improved detection of the biomarker in NSCLC * Lunit's AI solution is the first application in Guardant Galaxy, a suite of AI and other technology tools that enhance Guardant Health's portfolio of...

2023-01-31 21:05 2170

Lunit Highlights the Effectiveness of AI in Predicting Cancer Treatment Outcomes - Findings to be Presented at ASCO GI 2023

* Lunit to present two abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO as a biomarker to predict treatment outcomes in liver and colon cancer SEOUL, South Korea, Jan. 18,...

2023-01-18 21:00 1882

Lunit to Supply AI Solution for Chest X-Ray Analysis to Albert Einstein, Latin America's Largest Hospital

* Lunit signed a software license agreement with the Hospital Israelita Albert Einstein,Latin America's top medical institution, to provide its AI-based chest x-ray solution * Under the agreement, Lunit will supply its AI solution for chest x-ray image analysis to the Hospital Israelita Alber...

2023-01-04 21:20 2473

Lunit AI Can Help Tuberculosis Screening in Prisons, as Published in The Lancet Regional Health - Americas

* Recent study suggests that AI-based x-ray interpretation algorithms may be an efficient means to improve TB case detection among incarcerated populations * Lunit INSIGHT CXR showed the most superior performance among the tested cohort, with greater accuracy and generalizability among subgrou...

2022-12-15 21:00 1629

Lunit Partners with CARPL.ai to Accelerate AI-Powered Medical Imaging Across Major Overseas Channels

* Lunit signed a global distribution agreement to provide its AI-based radiology solutions for clinical use via CARPL.ai's platform * The partnership will deliver Lunit INSIGHT CXR and Lunit INSIGHT MMG for commercial use in the U.S.,Australia, Brazil, India, and Singapore SEOUL, South Korea,...

2022-11-23 12:30 3494

Lunit Becomes the First Medical Software Company in Asia-Pacific to Become MDR CE and UKCA Certified

* Lunit becomes first software as a medical device (SaMD) company in APAC to become MDR CE and UKCA certified * MDR and UKCA certifications are required for all Europe and UK commercial medical devices with implementation deadlines set to 2024 SEOUL, South Korea, Nov. 21, 2022 /PRNewswire/ --...

2022-11-21 21:00 2680

Lunit to Supply AI Platform to Australia's BreastScreen NSW Machine Reading Project

* Lunit's INSIGHT MMG solution has been selected for mammogram screening in Australia's BreastScreen NSW's AI evaluation and clinical integration project * Successful completion of project to be followed by 5-year operation contract with BSNSW to assist radiologists in examining 350,000 women ...

2022-11-16 21:11 3584

Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research--Findings to be Presented at SITC 2022

* Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping. * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development. SEOUL, South Korea, Nov. 7, ...

2022-11-07 21:00 2008

Real-World Application of Lunit INSIGHT to be Spotlighted at RSNA 2022 (Oral Presentations)

* 7 oral presentations and 1 e-poster highlighting Lunit's most up-to-date research on its AI solution for radiology, have been accepted by RSNA * Program will include studies evaluating the performance of Lunit's commercial AI software across massive real-world population groups * Software ...

2022-11-01 22:00 2339

Lunit Joins World Economic Forum Global Innovators Community

* Lunit invited to join the World Economic Forum's Global Innovators Community, an invitation-only group of the world's most promising start-ups and scale-ups at the forefront of technological and business model innovation * In 2020, Lunit was nominated among hundreds of candidates as one of t...

2022-10-26 21:00 2582

Lunit Showcases AI Solutions for Radiology at AOCR & KCR 2022

* Lunit participates in the 20th Asian Oceanian Congress of Radiology and 78th Annual Meeting of the Korean Society of Radiology (AOCR & KCR 2022) * Lunit's demonstration focuses on how radiologists and AI solutions can create synergy through combined workflows * Visitors invited to Lunit De...

2022-09-21 22:48 1580

New Study by Lunit and MGH Validates Effectiveness of AI as Aid in Chest X-Ray Interpretation - Published in JAMA Network Open

* Joint study with Massachusetts General Hospital proves that Lunit's AI-powered chest x-ray analysis software enhances the overall performance and efficiency of radiologists SEOUL, South Korea, Sept. 13, 2022 /PRNewswire/ -- A recent study published in

2022-09-13 22:16 1381

Lunit Introduces AI for TB Screening to Indonesia Ministry of Health Officials

* Lunit participated in the "Indonesia AI Healthcare Course," organized by South Korean Ministry of Science and ICT as a platform to experience AI image analysis solution and share tuberculosis diagnosis technology * The program aimed to increase awareness of the values of AI-assisted tubercu...

2022-09-07 21:00 3285

Lunit to Showcase 5 Abstracts at ESMO 2022

* Lunit to present five posters at ESMO 2022 featuring the company's AI-biomarker platform * Studies corroborate the capability of Lunit SCOPE suite to address an expanding set of clinical and research questions based on world-leading digital pathology AI SEOUL, South Korea, Sept. 5, 2022 /PR...

2022-09-05 21:00 2690

Lunit AI Solution for Breast Cancer Detection Wins Commercial Approval in Taiwan

* Lunit's AI solution for mammography received a class 2 medical device license from the Taiwan Food and Drug Administration * Lunit's latest commercial approval to accelerate expansion in the Taiwanese market SEOUL, South Korea, Aug. 25, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a leading...

2022-08-25 23:13 3793
12345